

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/026005
	Serial No.	10/777,517
	Applicant	Jost-Price et al.
	Filing Date	February 12, 2004
	Group	1612
	IDS Filed	September 22, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Ahmed et al., "Treatment of Refractory Temporal Arteritis with Adalimumab," <i>Clin. Rheumatol.</i> 26:1353-1355, 2007.
	Ardizzone et al., "Inflammatory Bowel Disease: New Insights Into Pathogenesis and Treatment," <i>J. Intern. Med.</i> 252:475-496, 2002.
	Badger et al., "Disease-Modifying Activity of SB 242235, A Selective Inhibitor of p38 Mitogen-Activated Protein Kinase, in Rat Adjuvant-Induced Arthritis," <i>Arth. Rheum.</i> 43:175-183, 2000.
	Beck et al., "Increased Production of Interferon Gamma and Tumor Necrosis Factor Precedes Clinical Manifestation in Multiple Sclerosis: Do Cytokines Trigger Off Exacerbations?" <i>Acta. Neurol. Scand.</i> 78:318-323, 1998.
	Braun et al., "Anti-Tumour Necrosis Factor α Therapy for Ankylosing Spondylitis: International Experience," <i>Ann. Rheum. Dis.</i> 61:iii51-iii60, 2002.
	Braun et al., "Therapy of Ankylosing Spondylitis and Other Spondyloarthritides: Established Medical Treatment, Anti-TNF- α Therapy and Other Novel Approaches," <i>Arth. Res.</i> 4:307-321, 2002.
	Cantini et al., "Treatment of Longstanding Active Giant Cell Arteritis with Infliximab: Report of Four Cases," <i>Arth. Rheum.</i> 44:2933-2935, 2001.
	Crew et al., "Transgenic Mice Expressing a Truncated <i>Peromyscus leucopus</i> TNF- α Gene Manifest an Arthritis Resembling Ankylosing Spondylitis," <i>J. Interferon Cytokine Res.</i> 18:219-225, 1998.
	Durie et al., "Collagen-Induced Arthritis as a Model of Rheumatoid Arthritis," <i>Clin. Immunol. Immunopathol.</i> 73:11-18, 1994.
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/026005
	Serial No.	10/777,517
	Applicant	Jost-Price et al.
	Filing Date	February 12, 2004
	Group	1612
	IDS Filed	September 22, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Edwards, "PEGylated Recombinant Human Soluble Tumour Necrosis Factor Receptor Type 1 (r-Hu-sTNF-RI): Novel High Affinity TNF Receptor Designed for Chronic Inflammatory Diseases," <i>Ann. Rheum. Dis.</i> 58:173-181, 1999.
	Elenkov et al., "Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity," <i>Ann. N.Y. Acad. Sci.</i> 966:290-303, 2002.
	Ettehadi et al., "Elevated Tumour Necrosis Factor-Alpha (TNF- α) Biological Activity in Psoriatic Skin Lesions," <i>Clin. Exp. Immunol.</i> 96:146-151, 1994.
	Feldmann et al., "Anti-TNF α Therapy of Rheumatoid Arthritis: What Have We Learned?" <i>Annu. Rev. Immunol.</i> 19:163-196, 2001.
	Field et al., "Immuno-Localisation of Tumour Necrosis Factor and Its Receptors in Temporal Arteritis," <i>Rheumatol. Int.</i> 17:113-118, 1997.
	Ganesan et al., "Therapeutic Inhibitors of Tumor Necrosis Factor in Crohn's Disease," <i>Curr. Opin. Invest. Drugs</i> 3:1301-1306, 2002.
	Gorman et al., "Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α ," <i>N. Eng. J. Med.</i> 346:1349-1356, 2002.
	Khoury et al., "Changes in Serum Levels of ICAM and TNF-R Correlate with Disease Activity in Multiple Sclerosis," <i>Neurology</i> 53:758, 1999.
	Krueger et al., "Potential of Tumor Necrosis Factor Inhibitors in Psoriasis and Psoriatic Arthritis," <i>Arch. Dermatol.</i> 140:218-225, 2004.
	Lichtenstein, "Is Infliximab Effective for Induction of Remission in Patients with Ulcerative Colitis?" <i>Inflammatory Bowel Diseases</i> 7:89-93, 2001.
	Mashkovsky, "Interactions Between Medicaments," <i>Novaya Volna</i> 1:11, 2001.
	Mashkovsky, "Interactions Between Medicaments," <i>Novaya Volna</i> 1:11, 2001. (English translation)
	Mashkovsky, "Adrenal Cortical Hormones and Synthetic Analogues Thereof," <i>Novaya Volna</i> 2:25, 2001.
	Mashkovsky, "Adrenal Cortical Hormones and Synthetic Analogues Thereof," <i>Novaya Volna</i> 2:25, 2001. (English translation)
	Martínez-Taboada et al., "A Double-Blind Placebo Controlled Trial of Etanercept in Patients with Giant Cell Arteritis and Corticosteroid Side Effects," <i>Ann. Rheum. Dis.</i> 67:625-630, 2008.
	Mattey et al., "Association of Giant Cell Arteritis and Polymyalgia Rheumatica with Different Tumor Necrosis Factor Microsatellite Polymorphisms," <i>Arth. Rheum.</i> 43:1749-1755, 2000.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No. 50164/026005 Serial No. 10/777,517 Applicant Jost-Price et al. Filing Date February 12, 2004 Group 1612 IDS Filed September 22, 2008
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Migliore et al., "TNF-alpha Blockade Induce Clinical Remission in Patients Affected by Polymyalgia Rheumatica Associated to Diabetes Mellitus and/or Osteoporosis: a Seven Cases Report," <i>Eur. Rev. Med. Pharmacol. Sci.</i> 9:373-378, 2005.
	Moreland et al., "Etanercept Therapy in Rheumatoid Arthritis," <i>Ann. Intern. Med.</i> 130:478-486, 1999.
	Mpofu et al., "Anti-TNF- α Therapies: They Are All the Same (Aren't They?)," <i>Rheumatology</i> 44:271-272, 2005.
	Murch et al., "Location of Tumour Necrosis Factor α by Immunohistochemistry in Chronic Inflammatory Bowel Disease," <i>Gut</i> 34:1705-1709, 1993.
	Nanda et al., "Etanercept: a Clinical Review of Current and Emerging Indications," <i>Expert. Opin. Pharmacother.</i> 5:1175-1186, 2004.
	Nikolaus et al., "Mechanisms in Failure of Infliximab for Crohn's Disease," <i>Lancet</i> 356:1475-1479, 2000.
	Raza, "Anti-TNF Therapies in Rheumatoid Arthritis, Crohn's Disease, Sepsis, and Myelodysplastic Syndromes," <i>Microsc. Res. Tech.</i> 50:229-235, 2000.
	Sandborn et al., "Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial," <i>Gastroenterology</i> 121:1088-1094, 2001.
	Sands, "Biological Therapies for Ulcerative Colitis," <i>Acta Gastro-Enterologica Belgica</i> 64:205-209, 2001.
	Schreiber et al., "Tumour Necrosis Factor α and Interleukin 1β in Relapse of Crohn's Disease," <i>Lancet</i> 353:459-461, 1999.
	Selmaj et al., "Identification of Lymphotoxin and Tumor Necrosis Factor in Multiple Sclerosis Lesions," <i>J. Clin. Invest.</i> 87:949-954, 1991.
	Sharief et al., "Association Between Tumor Necrosis Factor- α and Disease Progression in Patients with Multiple Sclerosis," <i>N. Eng. J. Med.</i> 325:467-472, 1991.
	Shen et al., "Current Therapeutic Recommendations, <i>Infliximab</i> for <i>Ulcerative Colitis</i> ," <i>J. Clin. Gastroenterol.</i> 38:741-745, 2004.
	Shou et al., "Identification of Blood Biomarkers of Rheumatoid Arthritis by Transcript Profiling of Peripheral Blood Mononuclear Cells From the Rat Collagen-Induced Arthritis Model," <i>Arthritis Res. Ther.</i> 8:R28, 2006.
	Sieper et al., "New Treatment Options in Ankylosing Spondylitis: a Role for Anti-TNF α Therapy," <i>Ann. Rheum. Dis.</i> 60:iii58-iii61, 2001.
	Song et al., "Serotonin Reuptake Inhibitors Reverse the Impairments in Behavior, Neurotransmitter and Immune Functions in the Olfactory Bulbectomized Rat," <i>Human Psychopharmacol.</i> 9:135-146, 1994.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/026005
		Serial No.	10/777,517
		Applicant	Jost-Price et al.
		Filing Date	February 12, 2004
		Group	1612
		IDS Filed	September 22, 2008
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	<p>Vladic et al., "Cerebrospinal Fluid and Serum Protein Levels of Tumour Necrosis Factor-Alpha (TNF-α), Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R gp80) in Multiple Sclerosis Patients," <i>Cytokine</i> 20:86-89, 2002.</p>

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.</p>	